[Metabolic and blood circulation evaluation of acute ischemic cerebral accident in humans using positron emission tomography].
Positron emission tomography and oxygen-15 were used to evaluate the effects of an almitrine-raubasine combination on cerebral blood flow and oxydation metabolism in patients with acute cerebral ischaemia. In 5 patients, aged between 58 and 74 years, with cerebral ischaemic accident in the territory of the middle cerebral artery, blood flow rate, oxygen consumption and brain oxygen extraction were measured before and after a 90-min intravenous infusion of almitrine bismesilate 15 mg and raubasine 5 mg. Only one patient presented with initial relative luxury perfusion, the intensity of which was reduced by the combined treatment. The other 4 patients had focal reduction of cerebral blood flow and oxygen consumption prior to treatment. Statistical analysis conducted on three cerebral areas (epicentre of the lesion, anterior and posterior juxtalesional areas and homologous heterolateral areas) showed a significant 3.6% increase of oxygen consumption in the epicentre, both hemispheres included, and a significant increase of cerebral blood flow in all three areas (3% on the healthy side, 13% on the diseased side). No significant change in oxygen extraction was demonstrated. The authors conclude that acute almitrine-raubasine treatment has beneficial effects on the brain immediately after a cerebral vascular accident, reflecting respect of the circulation-metabolism couple.
D000208:Acute Disease; D000368:Aged; D015765:Almitrine; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects*; D010879:Piperazines / Q000627:therapeutic use*; D046948:Secologanin Tryptamine Alkaloids; D014055:Tomography, Emission-Computed; D015016:Yohimbine / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000697:Central Nervous System Stimulants; D004338:Drug Combinations; D010879:Piperazines; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine; C005709:raubasine; D015765:Almitrine
Evaluation métabolique et circulatoire de l'accident cérébral ischémique aigu chez l'homme par tomographie d'émission positonique.